Loading clinical trials...

Research of Biomarkers in Duchenne Muscular Dystrophy Patients | Clinical Trials | Clareo Health

COMPLETED

Research of Biomarkers in Duchenne Muscular Dystrophy Patients

Research of Biomarkers for Disease Diagnosis, Disease Monitoring and Therapeutic Treatment Response in Duchenne Muscular Dystrophy Patients

NCT01380964•Genethon

View on ClinicalTrials.gov

Summary

The purpose of this study is to identify potential biomarkers for the diagnosis, disease progression assessment and response to treatment in patients with Duchenne Muscular Dystrophy.

Eligibility

Age

3 - 20 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•FOR PATIENTS:
•Diagnosis of DMD confirmed by genetic testing
•Age over 3 years
•Weight over 15 kg
•Informed consent signed
•FOR CONTROLS:
•Age over 3 years
•Male gender
•Weight over 15 kg
•Subjects with national health insurance coverage
+2 more criteria

Exclusion Criteria

•FOR PATIENTS:
•Concomitant chronic or acute muscular, endocrine, infectious, allergic or inflammatory disorder in the three weeks preceding the blood test
•Intake of medicines other than angiotensin-converting enzyme inhibitors, beta blockers, dietary supplements, vitamins, alendronate and methylphenidate. Steroids (and medicines prescribed with them such as calcium supplements and proton pump inhibitors) will be discussed
•Mental retardation or autism
•Vaccination or treatment with immunoglobulins within the three months preceding inclusion
•FOR CONTROLS:
•Concomitant chronic or acute muscular, neurological (including mental retardation and autism), infectious or inflammatory disorder in the three weeks preceding the blood test
•Vaccination or treatment with immunoglobulins within the three months preceding inclusion

Locations (1)

Institute of Myology

Paris, France

Key Dates

Start Date

June 1, 2011

Primary Completion Date

December 1, 2015

Completion Date

December 1, 2015

Last Updated

August 17, 2016

Enrollment

220

ACTUAL participants

Conditions

Duchenne Muscular Dystrophy (DMD)

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

NCT07037862

Duchenne Muscular Dystrophy (DMD)

View study

RECRUITINGNA

Fear of Falling in Muscular Dystrophy

NCT07129954

Fear of FallingDuchenne Muscular Dystrophy (DMD)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Research of Biomarkers in Duchenne Muscular Dystrophy Patients

Inclusion Criteria

Exclusion Criteria

A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Fear of Falling in Muscular Dystrophy

DMD Voice: Qualitative Interviews With Patients and Caregivers

Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy

Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy

A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.